Literature DB >> 3570363

C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance.

G Füst, Z Miszlay, E Czink, L Varga, K Pálóczi, G Szegedi, S R Hollán.   

Abstract

Clinical and laboratory correlations of low C1 and C4 levels previously found to be a characteristic feature of chronic lymphocytic leukaemia (CLL) were analysed. Abnormalities of C4 were restricted to stage 1, 2 and 3 of CLL, whereas in the more advanced disease (stage 4) only low C1 levels were found. It was demonstrated that the observed disorders were associated with an increased susceptibility of the patients for infections and impair the immune complex precipitation inhibiting capacity of the patients' sera as well.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570363     DOI: 10.1016/0165-2478(87)90110-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?

Authors:  Muhammad Bilal Abid; Jeremiah Stromich; Nathan D Gundacker
Journal:  Cancer Biol Ther       Date:  2018-08-27       Impact factor: 4.742

2.  Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia.

Authors:  L Varga; E Czink; Z Miszlai; K Pálóczi; A Bányai; G Szegedi; G Füst
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

Review 3.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

4.  Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL.

Authors:  O Middleton; E Cosimo; E Dobbin; A M McCaig; C Clarke; A M Brant; M T Leach; A M Michie; H Wheadon
Journal:  Leukemia       Date:  2014-05-02       Impact factor: 11.528

Review 5.  Immunological aspects in chronic lymphocytic leukemia (CLL) development.

Authors:  Ricardo García-Muñoz; Verónica Roldan Galiacho; Luis Llorente
Journal:  Ann Hematol       Date:  2012-04-12       Impact factor: 3.673

Review 6.  Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.

Authors:  Petra Langerbeins; Barbara Eichhorst
Journal:  Acta Haematol       Date:  2021-02-25       Impact factor: 2.195

Review 7.  Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.

Authors:  Aleksandra Kusowska; Matylda Kubacz; Marta Krawczyk; Aleksander Slusarczyk; Magdalena Winiarska; Malgorzata Bobrowicz
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 8.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

9.  A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.

Authors:  Regina Michelis; Tamar Tadmor; Masad Barhoum; Mona Shehadeh; Lev Shvidel; Ariel Aviv; Galia Stemer; Najib Dally; Naomi Rahimi-Levene; Mona Yuklea; Andrei Braester
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

Review 10.  Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy.

Authors:  Salvatrice Mancuso; Marta Mattana; Melania Carlisi; Marco Santoro; Sergio Siragusa
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.